Palliative oncology: thalidomide.
Am J Hosp Palliat Care
; 27(3): 198-204, 2010 May.
Article
em En
| MEDLINE
| ID: mdl-19843880
ABSTRACT
After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma. Its mechanism of action involves activation of the immune system, antiangiogenic effects, and inhibition of cytokines. Thalidomide does not interact with the cytochrome oxidase system. It is not significantly metabolized, but it does undergo nonenzymatic hydrolysis in plasma. The resulting products are inactive. Despite the potential adverse effects of peripheral neuropathy, constipation, deep vein thrombosis, somnolence, rash, and orthostatic hypotension, thalidomide is an effective first-line agent for multiple myeloma in combination with dexamethasone or melphalan and prednisone. It has also been studied in the palliative care of patients with cytokine-based syndromes such as anorexia-cachexia syndrome. This review describes its use in oncology, hematology, and palliative care.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cuidados Paliativos
/
Talidomida
/
Inibidores da Angiogênese
/
Imunossupressores
/
Oncologia
/
Mieloma Múltiplo
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Am J Hosp Palliat Care
Assunto da revista:
ENFERMAGEM
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Estados Unidos